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Abstract 
Mitochondrial liver disease (MLD), and in particular mitochondrial DNA (mtDNA) depletion 
syndrome (MDS) is an important cause of acute liver failure (ALF) in infancy. Early and 
accurate diagnosis is important since liver transplantation (LT) is often contraindicated. It is 
unclear which methods are the best to diagnose MLD in the setting of ALF.  
Objective. To determine the incidence of MLD in children under two with ALF and the 
utility of routine investigations to detect MLD. 
Methods. Thirty-nine consecutive infants with ALF were admitted to a single unit from 2009-
11. All were extensively investigated using an established protocol. Genes implicated in 
MDS were sequenced in all cases and tissue mtDNA copy number measured where available.  
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Results. Five infants (17%) had genetically proven MLD: DGUOK (n=2), POLG (n=2) and 
MPV17 (1). Four of these died whilst one recovered.  Two had normal muscle mtDNA copy 
number and 3 had normal muscle respiratory chain enzymes.  An additional 8 children had 
low hepatic mtDNA copy number but pathogenic mutations were not detected. One of these 
developed fatal multisystemic disease following LT while five who survived remain well 
without evidence of multisystemic disease up to 6 years later. Magnetic resonance 
spectroscopy did not distinguish between those with and without MLD. 
Conclusions.  
Low liver mtDNA copy number may be a secondary phenomenon in ALF. 
Screening for mtDNA maintenance gene mutations may be the most efficient way to confirm 
MLD in ALF in the first two years of life. 
 
Key words: Acute liver failure, Mitochondrial disease, Respiratory chain deficiency, 
Mitochondrial DNA depletion syndrome, Liver transplantation 
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What is known  
 Mitochondrial liver disease is an important cause of infantile liver failure 
 The most effective way to diagnose mitochondrial liver disease in the setting of liver 
failure is unclear  
 
What is new  
 Low hepatic mitochondrial DNA copy number may be a consequence of liver disease 
rather than a cause of liver disease. 
 Screening for known mutations causing mitochondrial liver disease may be the best 
diagnostic strategy.   
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Introduction 
Acute liver failure (ALF) in infancy is a rare and devastating disease which has a very poor 
outcome without liver transplantation (LT).  In approximately 20% of cases, infantile liver 
failure is caused by genetic mitochondrial liver disease (MLD) (1-3) with the commonest 
single entity being mitochondrial DNA (mtDNA) depletion syndrome (MDS).  
Mitochondria contain multiple copies of mtDNA. MDS is caused by mutations in nuclear 
genes involved in mtDNA replication or in the maintenance of the deoxynucleotide pools 
required for de novo mtDNA replication, resulting in a quantitative loss of mtDNA copy 
number (4).  Pathogenic mutations causing hepatocerebral  MDS have been described in a 
number of genes to date with the commonest reported being; - DGUOK(5), POLG(6), 
MPV17(7) and PEO1 (encoding the Twinkle helicase)(8). 
Normal mitochondrial function is contingent upon the expression of many other nuclear 
genes which encode constituent proteins of the respiratory chain, proteins needed for 
assembly of the respiratory chain or for translation of mtDNA-encoded proteins(9). 
Mutations in these genes can also cause MLD and in particular mutations in TRMU, which 
encodes an enzyme essential for post-transcriptional modification of mitochondrial tRNAs, 
can cause infantile ALF. Such cases are particularly important to recognise as there is a 
significant chance of spontaneous recovery with supportive treatment. (10;11)  
Definitive diagnosis of most nuclear encoded mitochondrial disorders is best established by 
recognizing two pathogenic mutations in known disease causing genes. However, in the 
absence of an informative family history this is time consuming. In the absence of a genetic 
diagnosis, laboratory diagnosis requires demonstrating abnormal respiratory chain function 
and/or loss of mtDNA copy number in clinically-relevant tissue(s).(12) The most commonly 
sampled tissue is muscle as it is easily accessible with well-established normal ranges(12), 
although in multisystemic presentations of mitochondrial disease, muscle respiratory chain 
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activities and mtDNA levels may be normal and muscle biopsy will a priori fail to detect 
isolated hepatic disease.(6) Consequently liver biopsy is often necessary, if feasible.  
However abnormalities of respiratory chain function or of mtDNA copy number in damaged 
liver tissue may not be due to genetic mitochondrial disease but may be a secondary change 
due to liver disease of other causes.(13) 
The aim of this study was to to determine the incidence of genetic mitochondrial disease in a 
group of children presenting with ALF aged less than two years and to determine the utility 
of routine investigations to detect mitochondrial disease. 
This study was registered as an audit of clinical practice at Birmingham Children’s Hospital 
NHS Trust. Children were investigated and managed according to an established in house 
clinical protocol (see Supplemental Digital Content 1, Protocol, 
http://links.lww.com/MPG/A753) and the study was registered as an audit of clinical practice 
at Birmingham Children’s Hospital NHS Trust. 
    
 Methods 
Methods are available online as Supplemental Digital Content 2 
(http://links.lww.com/MPG/A754).  
Results 
A total of 39 infants (20 female, 19 male) presented with ALF during the study period. 
Ethnicity was white (30), Asian (5) and black (4). Four were born prematurely and median 
birth weight was 2.7 kg (range 1.8-4.1). Median age at presentation was 17 days (1-689).  
There had been no affected siblings in these families previous to the study. There were two 
sets of siblings included, one being twins. Three children were from consanguineous families. 
Overall 10 infants died without LT during the acute illness and 18 survived without LT 
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(Table 1).  Eleven underwent LT of whom three died in the early post-operative period. There 
were 2 later deaths following transplantation; one from progressive multisystemic disease 
after 3 months and one from vascular complications 1 year later. One child with ornithine 
transcarbamylase (OTC) deficiency underwent elective LT 1 year after presentation because 
of metabolic instability and remains well 3 years later. One child (Subject 37) had recurrent 
episodes of ALF and he was subsequently shown to have mutations in NBAS 
(Neuroblastoma Amplified Sequence) causing recurrent acute liver failure syndrome 
(RALF).(16)  
The results of diagnostic investigations are summarised in Table 1. The largest aetiological 
group was infection, accounting for 12 cases, including proven HSV in 8 cases, enterovirus in 
3 and adenovirus in one. Four had inborn errors of metabolism; galactosaemia (2), OTC (1), 
RALF (1); four had neonatal haemochromatosis phenotype and 12 cases were indeterminate 
despite an extensive diagnostic work up.  
Five children (13%) were found to have genetically confirmed MLD all of whom had MDS. 
All were born at full term after normal pregnancies. Three were born to consanguineous 
parents. Median age at presentation was 110 days (9 days to 23 months).  The genetic causes 
were mutations in DGUOK (2), POLG (2) and MPV17 (1).  
Four of the five children with genetic MLD showed rapid deterioration and died within 3 
weeks of presentation. One child who was homozygous for a p.(Leu304Arg) mutation in 
POLG presented at 18 months old, recovered with supportive treatment only and remains 
well without evidence of liver disease 6 years later.  
In addition, there was one unexplained case (subject 24) with some features of genetic MLD. 
This was a female infant who became jaundiced and unwell on the first day of life. She 
developed progressive encephalopathy and coagulopathy with peak INR of 3.5. Muscle 
biopsy showed steatosis and mtDNA depletion studies were borderline in both muscle (49%) 
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and liver (39%).  Cranial MRI showed features of cerebral oedema only. She underwent LT 
aged 23 days. She made an initial smooth recovery but when aged three months developed 
evidence of cardiomyopathy and died of progressive systemic disease two months after LT. 
No evidence of a genetic cause of MLD was found.  
Clinical and laboratory features of the infants with genetically proven MLD compared to 
those with other causes of ALF are summarised in Table 2. Children with MLD tended to 
have lower birth weight and presented later but these differences were not significant. 
Similarly, there were no significant differences in the presenting laboratory values between 
the 2 groups. Although the median plasma lactate levels were similar between the groups, all 
infants with MLD had abnormal lactate values while these were initially normal in 9/34 
without MLD.    
Results of tissue studies and radiology are listed in Table 1 and summarised in Table 3. Liver 
histology was available in 21 cases. The dominant lesion was hepatocyte necrosis in 13 cases 
and this was accompanied by microvesicular steatosis in three cases. Including these three 
cases, significant microvesicular steatosis was present in eight cases overall. Three who had 
genetically-confirmed MLD had liver histology available and all showed microvesicular 
steatosis. The remaining four biopsies showed established fibrosis/cirrhosis (3) and 
unexplained macrophage storage material respectively.  
Liver mtDNA copy number results were available in 17 cases, two of whom had genetically 
proven MLD due to DGUOK. These two children had low (15%) and borderline (37%) liver 
mtDNA copy number. In 15 children without MLD, seven had normal mtDNA copy number 
in liver and eight had low levels of mtDNA; depletion (4) and borderline depletion (4). The 
causes of ALF in these eight children with decreased mtDNA copy number without 
genetically proven MLD were: indeterminate in six and one each of neonatal 
hemochromatosis and enterovirus infection. Two of these children died, two recovered 
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without LT and four underwent successful LT. One child, referred to earlier, underwent 
successful LT but died from apparent multisystemic disease 2 months later. None of the five 
survivors have shown evidence of multisystemic disease after up to six years follow up.  
Muscle biopsies were available in 12 cases. None showed specific changes suggestive of 
mitochondrial involvement such as ragged-red fibres. Increased intrafibre lipid was found in 
four of five children with MLD who underwent muscle biopsy but was only found in one of 
seven children without MLD. This latter child was the one who died of a multisystemic 
disease post LT.  Muscle mtDNA copy number data were available in 11 cases, four of whom 
had MLD. Two children with MLD had low mtDNA copy number; one of these had complex 
IV deficiency in muscle tissue and one had normal enzyme activities. Two children with 
MLD had normal mtDNA copy number, and both also had normal respiratory chain activity.  
Six of seven children without MLD had normal mtDNA copy number and, in the 4 cases 
where these were measured, they also had normal respiratory chain enzyme activities. One 
had an ambiguous muscle mtDNA copy number (47%). 
A total of 15 children underwent cranial magnetic resonance imaging (MRI) with diffusion-
weighted imaging and 10 had magnetic resonance spectroscopy (MRS). All five children 
with MLD had MRI imaging which in one case (who had POLG mutation) showed 
symmetrical posterior midbrain changes similar to those reported in mitochondrial disease.(4) 
Three showed cerebral oedema which had a cytotoxic or demyelination pattern in two cases 
and a vasogenic pattern in one. Two children had an initial normal MRI, but in one case 
repeat MRI showed progression to vasogenic cerebral oedema. Ten children without MLD 
had an MRI which was normal in three and showed cerebral oedema in seven, appearing 
cytotoxic in two and vasogenic in five. Five children with MLD had MRS which showed a 
lactate peak in three. Five children without MDS had MRS which showed a lactate peak in 
two. 
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Discussion 
Infantile ALF is a serious disorder with a variety of potential causes.  A structured, rapid 
approach to diagnostic investigations in tandem with identifying and treating correctable 
disorders is necessary. We have confirmed that MLD is an important cause of infantile ALF 
and that genetically confirmed MDS is the commonest entity in this group. The outlook for 
affected infants is very poor and early recognition is important in order to minimise 
unnecessary invasive investigations, to prevent inappropriate LT and to facilitate family 
counselling.  Ideally, diagnostic investigations should be available within days of 
presentation. The definitive method to diagnose MLD is by detection of two pathogenic 
mutations in recognised genes, hence some attempt at targeted mutation detection should be 
initiated at the time of initial presentation. This could later be reassessed if other diagnostic 
information becomes available. 
In the absence of pathogenic disease-causing mutations, the diagnosis of MLD depends on 
tissue studies. It has been a sine qua non in the investigation of suspected mitochondrial 
disease that an affected tissue should be studied. Our findings cast doubt on this approach in 
the setting of ALF.  We have found that reduced mtDNA copy number in affected liver tissue 
is not synonymous with genetically proven MDS. In three of the eight cases reported here 
plausible alternative causes of ALF were found. In the five unexplained cases we cannot 
definitely exclude mitochondrial disease as undetected genetic disorders may yet be present.  
However, for at least four of these cases, primary mitochondrial disease seems unlikely; no 
pathogenic mutations have been detected and no other evidence to support progressive 
mitochondrial disease has appeared even after prolonged follow up. One of these children, 
who developed a multisystemic disease post LT, did have some features of systemic 
mitochondrial disease but no genetic cause was detected.  
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There have been few studies examining the accuracy of low hepatic mtDNA copy number to 
diagnosis MLD where the primary presentation is with clinical liver disease. In end stage 
liver disease some studies have shown that low mtDNA copy number appeared to be specific 
for MDS(17), but in another study 10/45 unselected cases undergoing LT had low copy 
number.(18) Low ntDNA copy number has also been reported in Mauriac syndrome where 
the clinical findings are often reversible (19). In ALF low copy number appears to be very 
common irrespective of aetiology.  Helbling et al(17) found low mtDNA copy number in 29 
of 44 patients with ALF and all 3 cases reported by Lane et al(18) had decreased number.  
Decreased copy number were found even where a plausible non-mitochondrial cause of ALF 
existed. In contrast, Al-Hussaini and colleagues(1) found hepatic mtDNA copy number to be 
specific for MDS, but only 4 children where liver disease did not have a mitochondrial cause 
were studied.  
 
Overall these reports are consistent with our findings and suggest that liver disease, and 
especially ALF, may cause a secondary lowering of mtDNA copy number as a consequence 
of the primary disease. We cannot exclude that as yet undetected mutations in other genes 
underlie these examples of mtDNA depletions. An important part of this study however is the 
length of subsequent follow up which makes late sequela of unrecognized disease less likely. 
We also cannot comment as to whether the low mtDNA copy number contribute to the 
pathogenesis of ALF in these cases. What we can say is that clinical management decisions, 
including whether to proceed with transplantation, should not be influenced by hepatic 
mtDNA copy number in the absence of proven mutations. 
    
Rapid detection of pathogenic mutations in candidate genes remains the ideal method for 
diagnosis of MLD. The commonest causes of MLD are recessively-inherited mutations in 
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DGUOK, POLG, MPV17, PEO1 and TRMU. (1;7;20) Certainly, screening for mutations in 
these genes should be initiated at presentation with infantile ALF. The prioritisation of genes 
to screen will depend on local experience and available facilities, while recognising that this 
approach will only recognise a proportion of defects.  
 
Up to 1300 nuclear genes encode mitochondrial related proteins and the basis of many 
defects remain unknown(20). It is to be hoped that next generation screening (NGS) 
techniques, including custom captures of specific nuclear-mitochondrial genes or whole 
exome (WES) or whole genome sequencing (WGS), will transform this situation. For 
example, it is now possible to sequence the entire mitochondrial genome and all coding exons 
of the nuclear genes encoding mitochondrial proteins. Initial experience using this approach 
for children with suspected mitochondrial disease achieved a firm diagnosis in 24% of cases 
and a probable cause in a further 30%.(21) The major future challenge will be to ensure NGS 
results can be made available in a clinically relevant timescale i.e. within days if possible, and 
certainly within a fortnight, although this will vary according to local practice and laboratory 
diagnostic algorithms. 
 
Even establishing a molecular diagnosis does not absolutely establish prognosis. While 4 of 
the 5 cases showed rapid progression and death from systemic disease, one child with 
recessive POLG mutations recovered spontaneously; interestingly, she was homozygous for 
the p.(Leu304Arg) mutation that is usually associated with a late-onset POLG phenotype of 
sensory ataxic neuropathy with dysarthria and ophthalmoplegia rather than liver disease.(22) 
This mutation has been reported to cause ALF in compound with a second (p.(Ala467Thr)) 
heterozygous POLG mutation(23) which supports the observation of Tzoulis et al  that 
compound heterozygosity often has a worse prognosis than homozygous POLG 
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mutations.(24) Recent work has suggested that the pattern of mtDNA when visualized by 
fluorescence microscopy in cultured fibroblasts may also provide further prognostic 
information.(14) Spontaneous recovery from ALF has been previously recognised in at least 
one other child with POLG mutations(25) and emphasizes that, while LT is inappropriate in 
this group, these patients should not be denied appropriate supportive treatment. 
Recognising and defining CNS involvement in MLD is crucial in order to guide prognosis 
and management.  In ALF from other causes CNS involvement with encephalopathy is 
common and is generally reversible following successful LT. However in MLD such 
involvement may be a contraindication to LT. MRI abnormalities are common, but not 
invariable, in MLD and range from widespread generalised white matter changes to cortical 
atrophy to specific involvement of deeper brain structures.(1;4;26) These latter appear to be 
more specific for MLD but were found in only one of our cases. We found generalised 
abnormalities were common in ALF irrespective of cause and that there was a similar 
distribution between cytotoxic and vasogenic cerebral oedema whether or not liver failure 
was due to MLD. Similarly, MRS detection of a lactate peak did not provide useful 
discrimination between mitochondrial and non-mitochondrial causes. We did confirm that 
MRI changes may develop and evolve very quickly and that serial evaluation may be 
necessary. However, in this group of ill infants MRI only helped the decision on 
appropriateness of LT in a small proportion of cases. 
In conclusion, we have shown that MLD is an important cause of infantile ALF and that 
mutation detection is the most robust diagnostic method. 
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Table 1. Investigations and clinical outcome of 39 infants with acute liver failure admitted to Birmingham Children’s Hospital from 2009-11 
 
Subject 
No. 
Diagnosis Age at 
presentation 
(days) 
Initial 
serum 
lactate 
(mmol/l) 
Muscle 
Histology 
Muscle 
respiratory 
chain 
activity 
Muscle 
mtDNA 
copy 
number 
(%) 
Liver Histology Liver 
mtDNA 
copy 
number 
(%) 
Cranial MRI MR 
spectroscopy 
Mutations 
detected 
Outcome 
1 MDS (DGUOK) 9 7.2 Increased 
lipid 
Decrease in 
complex IV 
45.0 Micro and 
macrovesicular 
steatosis 
37.0 Vasogenic 
pattern 
cerebral 
oedema 
Lactate peak p.[Glu44Lys];
[Glu44Lys] 
Died. 
2 MDS (DGUOK) 16 25.0 Increased 
lipid 
Normal 50.0 Hepatocellular 
necrosis and 
microvesicular 
steatosis 
15.0 Vasogenic 
pattern 
cerebral 
oedema 
Lactate peak p.[Arg39X];[
Arg39X] 
Died. 
3 MDS (MPV17) 110 9.9 Increased 
lipid 
Decrease in 
complexes 
I-IV 
ND ND ND Normal Normal p.[Gln44X];[
Gln44X] 
Died. 
4 MDS (POLG) 477 6.0 Normal Normal 55.0 ND ND Cytotoxic 
pattern 
cerebral 
oedema 
Lactate peak p.[Thr914Pro
];[Ala467Thr] 
Died. 
5 MDS (POLG) 503 3.7 Increased 
lipid 
Normal 107.0 Micro and 
macrovesicular 
steatosis 
ND post mid 
brain lesion 
in keeping 
with 
mitochondri
al disease  
Normal p.[Leu304Ar
g];[Leu304Ar
g] 
Recovered. Remains well 
6 years later. 
6 HSV 8 8.5 ND ND ND Haemorrhagic 
necrosis 
83 ND ND None. Died following LT 
7 HSV 11 16.0 ND ND ND Haemorrhagic 
necrosis 
ND ND ND None. Died 
8 HSV 8   ND ND ND ND ND ND ND None. Recovered 
9 HSV 8   ND ND ND ND ND ND ND None. Recovered 
10 HSV 11   ND ND ND ND ND ND ND None. Recovered 
11 HSV 11   ND ND ND ND ND ND ND None. Died following LT 
12 HSV 21 6.4 ND ND ND ND ND ND ND None. Died 
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13 HSV 17 4.7 ND ND ND ND ND Vasogenic 
pattern 
cerebral 
oedema 
ND None. Recovered 
14 Enterovirus  6 22.4 ND ND ND ND ND ND ND None. Died 
15 Enterovirus  12   Normal Normal 54.0 Haemorrhagic 
necrosis 
34.0 ND ND None. Died following LT 
16 Enterovirus  9 9.6 ND ND ND ND ND Vasogenic 
pattern 
cerebral 
oedema 
Lactate peak None. Died 
17 Adenovirus 112   ND Normal ND ND ND Cytotoxic 
pattern 
cerebral 
oedema 
ND None. Recovered 
18 Indeterminate 498 5.6 ND ND ND Panacinar 
necrosis 
29.0 ND ND None. Successful LT 
19 Indeterminate 228 3.3 ND ND ND Microvesicular 
steatosis 
25.0 ND ND None. Recovered 
20 Indeterminate 52 3.8 ND ND ND Severe fibrosis 
and 
microvesicular 
steatosis 
40.0 ND ND None. Recovered. 
21 Indeterminate 349 4.7 ND ND ND Panacinar 
necrosis and 
macrovesicular 
steatosis 
42.0 ND ND None. Successful LT 
22 Indeterminate 260 1.2 ND ND ND ND ND ND ND None. Died 
23 Indeterminate 15 4.3 Normal Normal 127.0 Heaptocyte 
necrosis and 
macrophage 
storage 
material. 
91.0 Normal ND None. Died 
24 Indeterminate 1 3.0 Increased 
lipid 
ND 47.0 Panacinar 
necrosis 
39.0 Vasogenic 
pattern 
cerebral 
oedema 
ND None. Underwent LT but died of 
progressive 
multisystemic illness 2 
months later. 
25 Indeterminate  689 3.8 ND ND ND Hepatocellular 
necrosis and 
microvesicular 
steatosis 
60 ND ND None. Recovered 
26 Indeterminate  644 2.7 ND ND ND Panacinar 
necrosis 
92 ND ND None. Recovered 
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27 Indeterminate  1 2.1 Normal Normal 83.0 ND ND ND ND None. Recovered 
28 Indeterminate  37   Normal Normal 81.0 Moderate 
fibrosis. 
ND Normal ND None. Recovered 
29 Indeterminate  216 4.4 ND ND ND Panacinar 
necrosis 
25 Cytotoxic 
pattern 
cerebral 
oedema 
Normal None. Successful LT but died 1 
year later from vascular 
complications 
30 NH 8 4.7 ND ND ND ND ND ND ND None. Recovered. 
31 NH 24 3.2 Normal ND ND Panacinar 
necrosis 
65.0 ND ND None. Successful LT 
32 NH 21 0.7 ND ND ND Established 
cirrhosis 
54.0 ND ND None. Successful LT 
33 NH 13 1.0 Normal Normal 88.0 Panacinar 
necrosis 
26.0 Cytotoxic 
pattern 
cerebral 
oedema 
Normal None. Successful LT 
34 OTC deficiency 599 2.5 ND ND ND ND ND ND ND None. Recovered. Underwent 
elective LT age 3. 
35 Galactosemia 7   ND ND ND ND ND ND ND None. Recovered 
36 Galactosemia 9   ND ND ND ND ND ND ND None. Recovered 
37 RALF 539 5.8 ND Normal 80 Microvesicular 
steatosis 
127 Normal Normal None. Recovered and had 
subsequent recurrent 
bouts of liver failure. 
38 HLH 6 4.3 ND ND ND ND ND Vasogenic 
pattern 
cerebral 
oedema 
Lactate peak None. Died. 
39 Chemotherapy  121 6.6 ND ND ND Macro and 
microvesicular 
steatosis 
ND ND ND None. Recovered 
 
HSV, herpes simplex virus infection; NH, Neonatal haemochromatosis phenotype; OTC, Ornithine transcarbamylase deficiency; RALF, Recurrent acute liver 
failure and HLH,  Hemophagocytic Lymphohistiocytosis, MRI, Magnetic Resonance imaging; MRS, Magnetic Resonance spectroscopy; LT, Liver 
transplantation; ND, Not done. 
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 Table 2. Clinical and laboratory features in infant with and without genetically proven mitochondrial 
liver disease (MLD) as a cause of liver failure. 
 Genetically proven 
MLD 
 (n=5) 
Other causes of ALF 
 (n=34) 
P value 
Birth weight (kg) 2.6 (2.3 – 2.9) 2.8 (1.8 – 4.1) 0.76 
Age at presentation (days) 110 (9 – 503) 16 (1 – 689) 0.33 
Prothrombin time (seconds) 26 (23 – 41) 34 (18 – 120) 0.5 
Serum bilirubin ( mol/l) 113 (34 – 335) 146 (5– 492) 0.79 
ALT (IU/l) 113 (42 – 1875) 940 (19 – 6000) 0.11 
Lactate (mmol/L) 7.2 (3.7 – 25) 4.3 (0.7 – 22.4) 0.11 
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Table 3. Results of tissue studies and radiology where undertaken in infants with and without 
genetically proven mitochondrial liver disease (MLD). 
 Genetically 
proven MLD 
(n=5) 
Other causes of 
ALF 
(n=34) 
Liver mtDNA depletion 2/2 8/15 
Muscle  mtDNA depletion 2/4 1/7 
Abnormal muscle 
respiratory chain enzymes 
2/5 0/4 
Muscle steatosis 4/5 1/7 
Hepatic steatosis 3/3 5/18 
MRS lactate peak 3/5 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
